These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 31883735)
21. Prevalence of germline pathogenic Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677 [TBL] [Abstract][Full Text] [Related]
22. Identifying disparities in germline and somatic testing for ovarian cancer. Huang M; Kamath P; Schlumbrecht M; Miao F; Driscoll D; Oldak S; Slomovitz B; Koru-Sengul T; George S Gynecol Oncol; 2019 May; 153(2):297-303. PubMed ID: 30890269 [TBL] [Abstract][Full Text] [Related]
23. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study. Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165 [TBL] [Abstract][Full Text] [Related]
24. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K; J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631 [TBL] [Abstract][Full Text] [Related]
25. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel. Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864 [TBL] [Abstract][Full Text] [Related]
26. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231 [TBL] [Abstract][Full Text] [Related]
27. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246 [TBL] [Abstract][Full Text] [Related]
28. Clinical assays for assessment of homologous recombination DNA repair deficiency. Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552 [TBL] [Abstract][Full Text] [Related]
29. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562 [TBL] [Abstract][Full Text] [Related]
30. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684 [TBL] [Abstract][Full Text] [Related]
31. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111 [TBL] [Abstract][Full Text] [Related]
32. FLABRA, frontline approach for Giornelli G; Gallardo D; Hegg R; Abuin GG; La Vega M; Lim-Law M; Caceres V; Trujillo L; Pilar Estevez-Diz MD; Pacheco C; Sganga L; Goncalves S Future Oncol; 2021 May; 17(13):1601-1609. PubMed ID: 33415992 [No Abstract] [Full Text] [Related]
33. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998 [TBL] [Abstract][Full Text] [Related]
34. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373 [TBL] [Abstract][Full Text] [Related]
35. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552 [TBL] [Abstract][Full Text] [Related]
36. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan. Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534 [TBL] [Abstract][Full Text] [Related]
37. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857 [TBL] [Abstract][Full Text] [Related]
38. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053 [TBL] [Abstract][Full Text] [Related]
39. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First? Witjes VM; Ligtenberg MJL; Vos JR; Braspenning JCC; Ausems MGEM; Mourits MJE; de Hullu JA; Adang EMM; Hoogerbrugge N Gynecol Oncol; 2023 Jul; 174():121-128. PubMed ID: 37182432 [TBL] [Abstract][Full Text] [Related]
40. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT. Rybchenko LA; Poluben LO; Bychkova GM; Stephanovych GV; Klymenko SV Probl Radiac Med Radiobiol; 2019 Dec; 24():455-464. PubMed ID: 31841487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]